• KOL
    • KOLs Community
    • White
    • White Matter
    • Joanna Marguerite Wardlaw
    • Joanna Marguerite Wardlaw

      Joanna Marguerite Wardlaw

      UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom | Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK | ...

       

       

      KOL Resume for Joanna Marguerite Wardlaw

      Year
      2022

      UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom

      From the BHF Centre for Cardiovascular Science, University of Edinburgh, The Chancellor's Building, 49 Little France Crescent, EH16 4SB, Edinburgh, Scotland (J.K., M.S., G.M., M.J., S.I.S., C.A.C., A.A.S.T., S.D., M.R.D., E.J.R.v.B., D.E.N., M.C.W.); Centre for Heart Lung Innovation, St Paul's Hospital and University of British Columbia, Vancouver, Canada (S.S., J.L.); Laboratory Medicine Program, University Health Network, General Hospital, Toronto, Canada (M.A.S.); Royal Infirmary of Edinburgh, Edinburgh, Scotland (M.D., R.F., A.T., W.W., J.W.); Edinburgh Imaging, Queen's Medical Research Institute, Edinburgh, Scotland (G.M., S.I.S., T.M., E.J.R.v.B., D.E.N., M.C.W.); and Department of Medicine, Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif (P.J.S.).

      Centre for Clinical Brain Sciences, University of Edinburgh

      2021

      Centre for Clinical Brain Sciences, The University of Edinburgh, UK

      Geriatric Medicine, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

       

       

      Joanna Marguerite Wardlaw: Influence Statistics

      Sample of concepts for which Joanna Marguerite Wardlaw is among the top experts in the world.
      Concept World rank
      detection early signs #1
      rebleedingmanagement #1
      benefit intravenous treatment #1
      oct serum gh #1
      neurodegenerative magnetic #1
      strokologists #1
      infarct expansion 1h #1
      lesion area detection #1
      baseline dwi cbfsq #1
      delirium emotional lability #1
      diastolic fractional anisotropy #1
      patients rssi location #1
      wmh #1
      appearance scan #1
      cognition ischemic stroke #1
      mra neuroradiologists #1
      psifs participants #1
      clinical assessment stroke #1
      medi age #1
      svd features sle #1
      deep lacunar #1
      svd shrsp #1
      fast bfc bfc #1
      ischemic stroke wmh #1
      objectivesmri #1
      bmbs #1
      heart rate cilostazol #1
      death inflammatory markers #1
      dwi visible lesion #1
      95 thrombolysis #1
      spaces stroke #1
      hours stroke #1
      dep models #1
      microbleeds bmbs #1
      “disease evolution map #1
      clinically confirmed stroke #1
      minor lacunar #1
      vascular outcomes support #1
      r₁ r₂ mapping #1
      gtn 90 #1
      neck hydrocoil #1
      definitions detection #1
      nonparametric methods limits #1
      lotsim lesions segmentation #1
      diffusion imaging appearance #1
      baseline scans patients #1
      evidence evidencebased recommendations #1
      rtpa effects #1
      dwi cbfsq dwi #1
      total svd #1

       

      Prominent publications by Joanna Marguerite Wardlaw

      KOL-Index: 24823

      BACKGROUND: The majority of strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred. Successful treatment could mean that the patient is more likely to make a good recovery from their stroke. Thrombolytic drugs however, can also cause serious bleeding in the brain which can be fatal. Thrombolytic therapy has now been evaluated in several randomised trials in acute ...

      Known for Data Trials | Acute Ischaemic Stroke | Thrombolytic Therapy | 95 Death | Tissue Plasminogen
      KOL-Index: 23358

      BACKGROUND: Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase.

      METHODS: We did a pre-specified meta-analysis of individual patient data from 6756 patients in nine randomised trials comparing alteplase with placebo or open ...

      Known for Stroke Severity | Treatment Delay | Randomised Trials | Individual Patient Data | Patients Alteplase
      KOL-Index: 20907

      OBJECTIVES: To evaluate the accuracy of routinely available non-invasive tests (spiral computed tomographic angiography (CTA), time of flight magnetic resonance angiography (MRA), and colour Doppler ultrasound (DUS)), individually and together, compared with intra-arterial digital subtraction angiography (DSA) in patients with symptomatic tight carotid stenosis; and to assess the effect of substituting non-invasive tests for DSA on outcome, interobserver variability, and patient ...

      Known for Cta Mra | Carotid Endarterectomy | Sensitivity Specificity | Digital Subtraction | Angiography Dsa
      KOL-Index: 20743

      BACKGROUND: Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator (rt-PA), is licensed for use in selected patients within 4.5 hours of stroke in Europe and within three ...

      Known for Ischaemic Stroke | 80 Years | Thrombolytic Therapy | Treatment Rtpa | Extracted Data
      KOL-Index: 20128

      BACKGROUND: The cause of cerebral small vessel disease is not fully understood, yet it is important, accounting for about 25% of all strokes. It also increases the risk of having another stroke and contributes to about 40% of dementias. Various processes have been implicated, including microatheroma, endothelial dysfunction and inflammation. A previous review investigated endothelial dysfunction in lacunar stroke versus mostly non-stroke controls while another looked at markers of ...

      Known for Lacunar Stroke | Endothelial Dysfunction | Blood Markers | Tnf Α | Small Vessel
      KOL-Index: 18776

      BACKGROUND: Cerebral microbleeds are a neuroimaging biomarker of stroke risk. A crucial clinical question is whether cerebral microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom the rate of future intracranial haemorrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs. We therefore aimed to establish whether a large burden of cerebral microbleeds or particular anatomical patterns of cerebral ...

      Known for Ischaemic Stroke | Cerebral Microbleeds | Intracranial Haemorrhage | Pooled Analysis | Individual Patient Data
      KOL-Index: 18136

      BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to 6 h from stroke onset.

      METHODS: In this international, multicentre, randomised, open-treatment trial, patients were allocated to 0·9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA) or to ...

      Known for Recombinant Tissue | Stroke Trial | 6 Months | Rtpa Control | Intravenous Thrombolysis
      KOL-Index: 17824

      BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on ...

      Known for Antiplatelet Therapy | Intracerebral Haemorrhage | Participants Median | Label Trial | Occlusive Vascular Disease
      KOL-Index: 17523

      BACKGROUND: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke.

      METHODS: We did an international, partial-factorial, open-label, ...

      Known for Acute Ischaemic Stroke | Blood Pressure | Intravenous Alteplase | Functional Status | Intracranial Haemorrhage
      KOL-Index: 17395

      BACKGROUND: Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features ...

      Known for Antiplatelet Therapy | Intracerebral Haemorrhage | Stroke Risk | Small Vessel | Cerebral Microbleeds
      KOL-Index: 17118

      BACKGROUND: The majority of strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and could improve recovery after stroke. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator (rt-PA), is licensed for use in highly selected patients within three hours of stroke.

      OBJECTIVES: To ...

      Known for Ischaemic Stroke | Patients Trials | Thrombolytic Therapy | Treatment Hours | 95 Death
      KOL-Index: 17028

      BACKGROUND AND PURPOSE: In patients with acute ischemic stroke, a high blood pressure or a highly variable blood pressure is a common reason for withholding thrombolytic treatment, but guidelines recommend a conservative approach to active blood pressure lowering in this setting. We have performed exploratory analyses to study the clinical effects of blood pressure and early blood pressure-lowering treatment in patients included in a randomized-controlled trial of thrombolytic treatment ...

      Known for Blood Pressure | 24 Hours | Ischemic Stroke | Thrombolytic Treatment | 95 Confidence Interval
      KOL-Index: 16567

      BACKGROUND: General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies compared with patients treated without GA. We assessed functional outcome in ischaemic stroke patients with large vessel anterior circulation occlusion undergoing endovascular thrombectomy under GA, versus thrombectomy not under GA (with or without sedation) versus standard care (ie, no thrombectomy), stratified by the use of GA versus standard ...

      Known for Endovascular Thrombectomy | Functional Outcome | General Anaesthesia | Ischaemic Stroke | Individual Patient Data
      KOL-Index: 16307

      BACKGROUND: Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients.

      METHODS: We used individual patient data from the Stroke Thrombolysis Trialists' (STT) ...

      Known for Intracerebral Haemorrhage | Acute Ischaemic Stroke | Patients Alteplase | Individual Patient Data | Secondary Analysis
      KOL-Index: 15212

      RATIONALE: As the population of the world ages, age-related cognitive decline is becoming an ever-increasing problem. However, the changes in brain structure that accompany normal aging, and the role they play in cognitive decline, remain to be fully elucidated.

      AIMS: This study aims to characterize changes in brain structure in old age, and to investigate relationships between brain aging and cognitive decline using the Lothian Birth Cohort 1936. Here, we report the rationale, design ...

      Known for Lothian Birth Cohort | Brain Aging | Vascular Disease | Cognitive Decline | White Matter Lesions

      Key People For White Matter

      Top KOLs in the world
      #1
      Stephen M Smith
      uk biobank functional connectivity multiple sclerosis
      #2
      Mark Jenkinson
      multiple sclerosis white matter uk biobank
      #3
      Paul McMahan Matthews
      multiple sclerosis magnetic resonance uk biobank
      #4
      Heidi Johansen‐Berg
      white matter multiple sclerosis physical activity
      #5
      Timothy Edward John Behrens
      prefrontal cortex white matter human connectome project
      #6
      †Susumu Mori
      white matter diffusion tensor imaging magnetic resonance

      Joanna Marguerite Wardlaw:Expert Impact

      Concepts for whichJoanna Marguerite Wardlawhas direct influence:White matter,  Ischemic stroke,  Lacunar stroke,  Magnetic resonance,  Ischaemic stroke,  Acute stroke,  Acute ischaemic stroke,  Blood pressure.

      Joanna Marguerite Wardlaw:KOL impact

      Concepts related to the work of other authors for whichfor which Joanna Marguerite Wardlaw has influence:Ischemic stroke,  White matter,  Cognitive impairment,  Magnetic resonance,  Intravenous thrombolysis,  Mechanical thrombectomy,  Cerebral microbleeds.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom | Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK | Centre for Clinical Brain Sciences, UK Dementia Research Institute, Univers

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.